11848EGP
- Active ingredient
- lapatinib
- Strength
- 250mg
- Form
- tablet
- Manufacturer
- glaxo smithkline > novartis
- Route
- oral.solid
Uses
Used in combination regimens for HER2-positive advanced or metastatic breast cancer.
Do not use if
Contraindicated in patients with severe hypersensitivity to lapatinib or its components.
Side effects
Common adverse effects include diarrhea, rash, nausea, vomiting, fatigue, and palmar-plantar erythrodysesthesia.
Warnings
May cause severe hepatotoxicity. Liver function monitoring is required during treatment.
How it works
A tyrosine kinase inhibitor that targets HER2 and EGFR signaling pathways involved in tumor growth.
Storage
Store at controlled room temperature in the original container.